secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2022-03-31T23:59:59+00:00
Accession:  0000950170-22-005242
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics Q4 2021 net loss $19.1M; PRISM4 trial on hold, CFO retiring
------------------------------------------------------------------------------

- Net loss of $19.1M in Q4 2021 ($13.1M in Q4 2020); full year loss $58.2M ($39.3M in 2020).
- Cash and equivalents $133.5M at Dec 31, 2021; expected to fund operations into mid-2023.
- PRISM4 Phase 3 trial of CP101 in recurrent C. difficile remains on clinical hold; at least one quarter delay.
- Paused development of CP101 for chronic HBV to focus on CDI and autism programs.
- CFO Greg Perry to retire April 30, 2022; COO Marc Blaustein to serve as principal financial officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022005242/0000950170-22-005242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022005242/fnch-20220331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-005242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer